Thursday, February 18, 2021 4:17:51 PM
I agree iwasadiver, I also believe that the main reason Charles River Laboratories bought Cognate was because of the long-term worldwide revenue prospects for DCVax-L & DCVax Direct, and the upside stock appreciation potential of the 12 million NWBio shares.
I am going to repeat what I said to Bob_LobLaw:
I believe $875 million to acquire Cognate is cheap, given the upside revenue & stock price potential for NWBio. But, it is a very good long-term strategic move for both Cognate, Charles River Laboratories & NWBio. I also expect that CRL will purchase Advent Bioservices at some point in the future.
My guess is that the senior management of Cognate will continue to run the Memphis facility, and they will be granted a lot of CRL stock options.
This will give NWBio almost an instant global footprint for DCVAx-L & DCVax Direct. After approval for ndGBM & rGBM, I am expecting dozens of more approvals worldwide for both operable & inoperable solid tumor cancers.
CRL will make multiple billions of dollars off of this deal going forward.
I am going to repeat what I said to Bob_LobLaw:
I believe $875 million to acquire Cognate is cheap, given the upside revenue & stock price potential for NWBio. But, it is a very good long-term strategic move for both Cognate, Charles River Laboratories & NWBio. I also expect that CRL will purchase Advent Bioservices at some point in the future.
My guess is that the senior management of Cognate will continue to run the Memphis facility, and they will be granted a lot of CRL stock options.
This will give NWBio almost an instant global footprint for DCVAx-L & DCVax Direct. After approval for ndGBM & rGBM, I am expecting dozens of more approvals worldwide for both operable & inoperable solid tumor cancers.
CRL will make multiple billions of dollars off of this deal going forward.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
